Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation

Transplant Proc. 1998 Aug;30(5):2159-60. doi: 10.1016/s0041-1345(98)00572-7.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Azathioprine / therapeutic use
  • Cyclosporine / therapeutic use
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Immunosuppression / methods*
  • Immunosuppressive Agents / therapeutic use*
  • Liver Transplantation / immunology*
  • Liver Transplantation / mortality
  • Placebos
  • Prednisolone / therapeutic use
  • Receptors, Interleukin-2 / immunology*
  • Survival Rate
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Placebos
  • Receptors, Interleukin-2
  • Cyclosporine
  • Prednisolone
  • inolimomab
  • Azathioprine